Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy

Metabolic Brain Disease

Volumn 17, Issue 4, 2002, Pages 453-462

  Kircheis, G ^a   Wettstein, M ^a   Vom Dahl, S ^a   Haussinger D ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Hepatic encephalopathy; Hyperammonemia, placebo controlled clinical trials; L ornithine L aspartate

Indexed keywords

AMMONIUM CHLORIDE; ORNITHINE ASPARTATE; PLACEBO; PROTEIN;

AMMONIA FORMATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DETERIORATION; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERAMMONEMIA; LIVER CIRRHOSIS; MENTAL HEALTH; MENTAL PERFORMANCE; NAUSEA; NUMBER CONNECTION TEST A; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL; VOMITING;

AMMONIA; DIPEPTIDES; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER CIRRHOSIS; MUSCULAR DISEASES; SEVERITY OF ILLNESS INDEX;

EID: 0036988608     PISSN: 08857490     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021934607762     Document Type: Conference Paper

References (22)

1. Conn, H.O. (1994). The theoretic therapy of hepatic encephalopathy. In: Conn, H.O., and Bircher, J., (eds.), Hepatic Encephalopathy: Syndromes and Therapies, Medi-Ed Press, East Lansing, MI, pp. 135-148.
2. Cooper, A.J.L., Lai, J.C.R., and Gelbard, A.S. (1989). Ammonia in liver and extrahepatic tissues: An overview of metabolism and toxicity in mammals. In: Butterworth, R.F., Pomier-Layrargues, G. (eds.), Hepatic Encephalopathy: Pathophysiology and Treatment, Humana Press, Clifton, pp. 27-48.
3. Fleig, W.E., Kircheis, G., Spengler, U., Zeuzem, S.T., Görtelmeyer, R., and The German-Austrian-Swiss Multicenter Study Group (1999). Placebo-controlled, double-blind evaluation of L-ornithine-L-aspartate (LOLA) granules in patients with cirrhosis and subclinical (SHE) or mild overt hepatic encephalopathy (HE). J. Hepatol. 30(Suppl. 1):65 (abstract).
4. Häussinger, D. (1983). Hepatocyte heterogeneity in glutamine and ammonia metabolism and the role of an intercellular glutamine cycle during ureogenesis in perfused rat liver. Eur. J. Biochem. 133:269-274.
5. 4-induced liver cell necrosis with no effect on urea synthesis. Chem. Biol. Interact. 48:191-194.
6. Henglein-Ottermann, D. (1976). Der Einfluß von Ornithin-Aspartat auf die experimentell erzeugte Hyperammoniämie. Klinisch-experimentelle Studie. Therapie der Gegenwart 115:1504-1518.
7. Jessy, J., Mans, A.M., DeJoseph, M.R., and Hawkins, R.A. (1990). Hyperammonaemia causes many of the changes found after portacaval shunting. Biochem. J. 272:311-317.
8. Kaiser, S., Gerok, W., and Häussinger, D. (1988). Ammonia and glutamine metabolism in human liver slices: New aspects of the pathogenesis of hyperammonemia in chronic liver disease. Eur. J. Clin. Invest. 18:535-542.
9. Kalk, H. (1958). Die Klinik der akuten Leberinsuffizienz. Gastroenterologia 90:271-290.
10. Kircheis, G., Metz, M., Frey, S., and Seiller, E. (1996). Correlation between pharmacokinetic aspects and clinical efficacy of L-ornithine-L-aspartate (OA): Results of randomized, controlled clinical trials. J. Hepatol. 25(Suppl. 1):131 (abstract).
11. Kircheis, G., Nilius, R., Berndt, H., Buchner, M., Held, C., Hendricks, R., et al. (1997). Therapeutic efficacy of L-ornithine-L-aspartate infusion concentrate in patients with liver cirrhosis and hepatic encephalopathy: A placebo-controlled double-blind study. Hepatology 25:1351-1360.
12. Leonhardt, H., and Bungert, H.J. (1972). Therapie der schweren Hyperammoniämie. Med. Klin. 67:1052-1056.
13. Molimard, R., Charpentier, C., and Lemonnier, F. (1982). Modifications de l'amino-acidémie des cirrhotiques sous l'influence de sels d'ornithine. Ann. Nutr. Metab. 26:25-36.
14. Morrison, W.L., Bouchier, I.A.D., Gibson, J.N.A., and Rennie, M.J. (1990). Skeletal muscle and whole-body turnover in cirrhosis. Clin. Sci. 78:613-619.
15. Pomier-Layrargues, G., Giguere, J.F., Lavoie, J., and Butterworth, R.F. (1989) Treatment of hepatic encephalopathy. New perspectives on old ideas. In: Pomier-Layrargues, G., and Butterworth, R.F. (eds.), Hepatic Encephalopathy. Pathophysiology and Treatment, Mumana Press, Clifton, New Jersey, pp. 469-481.
16. Reynolds, N., Downie, S., Smith, K., Kircheis, G., and Rennie, M.J. (1999). Treatment with L-ornithine-L-aspartate infusion restores muscle protein synthesis responsiveness to feeding in patients with cirrhosis. J. Hepatol. 30(Suppl. 1):65 (abstract).
17. Riordan, S., and Williams, R. (1997). Treatment of Hepatic Encephalopathy. New Engl. J. Med. 337:473-478.
18. Staedt, U., Leweling, H., Gladisch, R., Kortsik, C., Hagmüller, E., and Holm, E. (1993). Effects of ornithine aspartate on plasma ammmonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design. J. Hepatol. 19:424-430.
19. Stauch, S., Kircheis, G., Adler, G., Beckh, K., Ditschuneit, H., Görtelmeyer, R., et al. (1998). Oral L-ornithine-Laspartate therapy of chronic hepatic encephalopathy: Results of a placebo-controlled double-blind study. J. Hepatol. 28:856-864.
20. Stoll, B., and Häussinger, D. (1989). Functional hepatocyte heterogeneity: Vascular oxoglutarate is almost exclusively taken up by perivenous glutamine-synthetase-containing hepatocytes. Eur. J. Biochem. 181:709-716.
21. Stoll, B., McNelly, S., Buscher, H.P., and Häussinger, D. (1991). Functional hepatocyte heterogeneity in glutamate, aspartate and α-ketoglutarate uptake: A histoautoradiographical study. Hepatology 13:247-253.
22. Weller, M. (1962). Die Ver Wendemyder Berthelotslien Reubtian Auf Anmnaick.